LLY Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Eli Lilly and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$927.00 |
| 52 Week High | US$946.50 |
| 52 Week Low | US$760.30 |
| Beta | 0.42 |
| 11 Month Change | -2.06% |
| 3 Month Change | 2.59% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 21.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| LLY | PE Pharmaceuticals | PE Market | |
|---|---|---|---|
| 7D | -2.1% | -0.07% | 1.2% |
| 1Y | n/a | -13.9% | 6.6% |
Return vs Industry: Insufficient data to determine how LLY performed against the PE Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how LLY performed against the PE Market.
Price Volatility
| LLY volatility | |
|---|---|
| LLY Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 2.7% |
| 10% most volatile stocks in PE Market | 5.6% |
| 10% least volatile stocks in PE Market | 0.8% |
Stable Share Price: LLY has not had significant price volatility in the past 3 months.
Volatility Over Time: LLY's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of PE stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1876 | 43,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
| LLY fundamental statistics | |
|---|---|
| Market cap | US$790.38b |
| Earnings (TTM) | US$7.34b |
| Revenue (TTM) | US$38.92b |
107.6x
P/E Ratio20.3x
P/S RatioIs LLY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LLY income statement (TTM) | |
|---|---|
| Revenue | US$38.92b |
| Cost of Revenue | US$7.49b |
| Gross Profit | US$31.43b |
| Other Expenses | US$24.09b |
| Earnings | US$7.34b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 30, 2024
| Earnings per share (EPS) | 8.15 |
| Gross Margin | 80.75% |
| Net Profit Margin | 18.86% |
| Debt/Equity Ratio | 212.9% |
How did LLY perform over the long term?
See historical performance and comparison